The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
ThermoFisher Scientific Patheon Pharma Services
×
Recent searches Clear History
Suggestions
All Results
 Search
 US | EN

CPHI Frankfurt 2025

The conversation starts here.

October 28–30, 2025

In-person

Frankfurt, Germany

Booth: 5.1A8

Event website

Amid economic pressures, regulatory shifts, and rising complexity, the need for reliable, agile partners has never been greater. At CPHI Frankfurt 2025, we’re bringing together global expertise, integrated capabilities, and scientific depth to help you keep progress moving—wherever you are in the world, in your program, or in the face of disruption.

Why visit Thermo Fisher Scientific at CPHI?

Whether you’re planning your first IND or managing commercial-scale production, Accelerator™ Drug Development, 360° CDMO and CRO solutions are designed to flex with your needs and reduce development friction. With a global network and a commitment to partnership, we help streamline transitions, shorten timelines, and provide clarity in a world of constant change.

Let’s talk about how we can help you:

  • Navigate global complexity with geographic agility and regulatory foresight
  • Build seamless pathways from early development through commercialization
  • Adapt to evolving market demands without losing momentum
  • Stay aligned across phases, functions, and teams

By connecting development, manufacturing, bioprocessing, and clinical supply services, we bring the clarity and continuity you need to move forward faster and with confidence.

Let’s start the conversation in Frankfurt.

Mark your calendar for this can’t-miss session

Jennifer Cannon - Thermo Fisher Scientific - CPHI Milan

“What’s your next move—and what will it cost you? Driving value under pressure”

  • Date: Wednesday, October 29, 2025

  • Time: 1:30 – 1:55 p.m. CET (25 minutes)

  • Location: Hall 4.1 - 4.1L8

Featuring Jennifer Cannon, President of Commercial Operations, Thermo Fisher Scientific.

In today’s high-pressure development landscape, every decision carries weight. From emerging biotechs navigating investment challenges on the path to IND, to established biopharma scaling complex programs toward commercialization, companies of all sizes are under increasing pressure to innovate, move fast, and deliver measurable value.

In this environment, traditional development models can slow progress, increase risk, and quietly drain time, money, and competitive advantage from a program. This session will examine a development model that’s reshaping expectations by unifying scientific, manufacturing, and clinical execution to unlock value at every stage.

Attendees will learn:

  • Where disjointed execution models create risk, delays, and added cost in drug development
  • What new data reveals about the ROI and timeline advantages of coordinated outsourcing
  • How companies are adjusting execution strategies to maintain momentum under pressure

Be sure to attend our other panel discussions

Jennifer Cannon’s can’t-miss session is just the beginning. Thermo Fisher Scientific experts will also share their insights during two panel discussions on Tuesday, October 28, and Thursday, October 30.

Check out the full details below:

Panel #1

CDMOs at a crossroads: Scaling, adapting, and partnering for the future

Date: Tuesday, October 28, 2025
Time: 11:35 a.m. – 12:20 p.m. CET
Track: Hall 4.1-L8

Featuring Dr. Anil Kane, Ph.D., MBA, Global Head of Technical and Scientific Affairs, Thermo Fisher Scientific

The CDMO industry is at an inflection point. The explosive demand for GLP-1 therapies is straining manufacturing capacity, forcing rapid investment in specialized capabilities. Geopolitical tensions are disrupting supply chains, making regional diversification and de-risking strategies more critical than ever. Meanwhile, raw material shortages, rising costs, and labor constraints are challenging production efficiency—pushing CDMOs toward automation and digitalization. At the same time, pharma companies are no longer just looking for vendors; they need long-term strategic partners who can offer flexibility, scalability, and innovation.

Panel #2

Redrawing the pharma investment map: How trade, commercialization, and policy are reshaping capital flows

Date: Thursday, October 30, 2025
Time: 11:35 a.m. – 12:20 p.m. CET
Track: Hall 4.1

Featuring Kelly McGinnis, President of Business Operations, Thermo Fisher Scientific

Global pharmaceutical manufacturing is undergoing a fundamental shift, driven by rising trade frictions, evolving industrial policy, and strategic decoupling. Governments are increasingly focused on supply chain resilience, leading to targeted tariffs, reshoring incentives, and localized production mandates. At the same time, capital allocation is being reshaped by the growing influence of commercialization strategies—particularly around speed-to-market, IP protection, and regulatory harmonization across key regions.

Nowhere is this more evident than in the United States, where evolving drug pricing policy—especially around Medicare negotiations and international reference pricing—is creating new pressures on profitability and risk-adjusted returns. This policy uncertainty is prompting investors to reassess market-entry strategies and revisit the viability of previously dominant production geographies.

Together, these forces are redrawing the global pharma investment map—redirecting capital away from legacy hubs toward regionally aligned, politically secure ecosystems that offer both commercial advantage and policy predictability.

 

Find your missing element with Thermo Fisher Scientific

Insights and resources

Discover a different kind of CDMO at CPHI

 

Continuing education for the pharma industry 

 

Follow us on social for event updates